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ABSTRACT

The invention is generally directed toward an analytical
method to determine the concentration of the free analyte
fraction in a Sample. More particularly, the method encom
passes applying a Sample comprising a free and bound
analyte fraction to an affinity column capable of Selectively
extracting the free fraction in the millisecond time domain.
The Signal generated by the free fraction is then quantified
by Standard analytical detection techniques. The concentra
tion of the free fraction may then be determined by com
parison of its signal with that of a calibration curve depicting
the Signal of known concentration of the same analyte.
24 Claims, 8 Drawing Sheets
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2
use of an additional binding reagent or Separation proceSS

ANALYSIS OF FREE ANALYTE FRACTIONS
BY RAPIDAFFINITY CHROMATOGRAPHY

that interacts with the free or bound fraction and causes the

equilibrium between these fractions to be altered. For
example, techniques with long analysis times, on the order

REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No.
09/776,800 filed on Feb. 5, 2001, now pending, which is
hereby incorporated by reference in its entirety.
This invention was made with Government support under
Grant No. 5 RO1 GMO44931 awarded by the National

5

of Solutes from the bound fraction which is then detected

with the original free fraction. The end result is an error in
the apparent concentration of free fraction that is measured.
In addition, many of these techniques Suffer from non

Institute of General Medical Sciences. The Government has

Specific interactions (e.g., binding of drugs to dialysis or
filtration membranes), and are limited to only certain types
of analytes (as is the case with natural filtrates).

certain rights in this invention.
FIELD OF THE INVENTION

The invention is directed toward an analytical method to
determine the concentration of the free analyte fraction in a
Sample. More particularly, the method encompasses the use
of affinity chromatography to determine the concentration of
the free analyte fraction in a Sample.

15

SUMMARY OF THE INVENTION

Many drugs, hormones, and toxins exist in two distinct

forms as they pass through the blood stream: 1) a fraction

that is non-covalently bound to proteins or other blood

25

Solution. The free and bound fractions are present in a
dynamic State, in which Solutes in one State are continually
eXchanging with those in the other. Accordingly, in biologi
cal Systems this proceSS is constant and an equilibrium is
formed between the free and bound fractions.

It has long been hypothesized that the free fraction of such
Substances is the biologically-active form, Since it is this
form which crosses cell membranes and interacts with cell

receptors or other target ligands. Because the free fraction is
the biologically-active form, this makes analysis of free
fractions of these Substances of particular interest in clinical
chemistry and pharmaceutical Science as a means for con
trolling and studying their effects within the body.
For many Substances it is possible to use their total

35

40

concentrations in blood or Serum as estimates of their free

levels by assuming there is a constant relationship between
these two types of values. However, there are numerous
Situations where this approach does not provide meaningful,
or even remotely accurate information. For example, after
Surgery, during malnutrition or pregnancy, and in various

45

fraction passes through the column, detection of Signal from

the free analyte fraction Separated from the sample in (a)
50

above, detection of Signal from the free analyte fraction

Separated from the standard in (b) above, generating a
calibration curve based upon the signal detected in (d)

(e.g., in newborns or the elderly) and in situations where

Several drugs and/or endogenous agents compete for the
Same binding proteins. A drug with a high total concentra
tion versus its binding proteins also createS problems when
trying to estimate the free fraction based upon total protein
concentrations Since this may result in a non-linear relation
ship between the drugs total and free levels.
Although Several analytical methods have been developed
in an attempt to determine the free fraction, all of these
methods are plagued with inherent inaccuracies or are
lengthy and tedious to perform. Examples of these methods
include equilibrium dialysis, ultrafiltration and the use of
natural filtrates, Such as tears or Saliva. A major problem
with these techniques is that the analysis often involves the

Among the Several aspects of the invention therefore, is
provided a method to determine the concentration of a free
analyte fraction in a Sample, the Sample comprising a bound
analyte fraction and the free analyte fraction, the method
comprising applying the Sample to an affinity column
wherein the column Separates the free analyte fraction from
the Sample in the millisecond time domain, detection of
Signal from the free analyte fraction Separated from the
Sample, and determining the concentration of free analyte
present in the Sample.
In yet another aspect of the invention is provided a
method to determine the concentration of a free analyte
fraction in a Sample, the Sample comprising a bound analyte
fraction and a free analyte fraction, the method comprising
applying the Sample to an affinity column, the column
Separating the Sample into the free analyte fraction and the
bound analyte fraction in the millisecond time domain
wherein the free analyte fraction is adsorbed to the column
and the bound analyte fraction passes through the column,
applying a Series of Standards to the affinity column wherein
each Standard applied comprises a known concentration of
the Same free analyte present in the Sample, the column
Separating each of the Standards into a free fraction and a
bound fraction in the millisecond time domain wherein the
free fraction is adsorbed to the column and the bound

disease states (e.g., cancer, renal failure or liver disease)
there can be a large fluctuation in the concentration of
binding proteins present in blood. This can Shift the equi
librium between these proteins and drugs that bind to them
and concomitantly cause a change in a drugs free fraction
even though its total concentration remains unaffected.
Similar shifts in drug-protein binding can occur with age

Accordingly, a need exists to determine the free fraction
without impacting the equilibrium between the free and
bound fractions of the Solutes. Equally, a need exists for a
method that is highly specific and can be employed to
determine the free fraction of a vast number of different
Substances.

BACKGROUND OF THE INVENTION

components and 2) a fraction that is non-bound, or free, in

of Several Seconds, results in bias in the measurement

process because it allows the release of a significant amount

55

above, the curve comprising a graph of the concentration of
free analyte present in each Standard Versus the Signal
detected for each concentration, and determining the con
centration of the free analyte fraction present in the Sample

by comparing the Signal detected in (c) above with the
calibration curve in (e) above.
60

65

Yet a further aspect of the invention provides a method to
determine the concentration of a free analyte fraction in a
Sample, the Sample comprising a bound analyte fraction and
a free analyte fraction, the method comprising applying the
Sample to an affinity column, the column Separating the
Sample into the free analyte fraction and the bound analyte
fraction in the millisecond time domain wherein the free

analyte fraction is adsorbed to the column and the bound
analyte fraction passes through the column, applying the

US 6,720,193 B2
4
IDX620 um microcolumn. These results represent the aver
age of triplicate analyses.
FIG. 4 depicts release of protein-bound S-warfarin fol
lowing the instantaneous removal of this drugs free fraction
from an equilibrium mixture of S-warfarin and HSA. The
graph in (a) shows the progression of this reaction over ten
Seconds, while the plot in (b) shows an expanded view on the
Sub-Second time Scale. These graphs were generated for a

3
Sample set forth in (a) to an inert control column wherein the

free analyte fraction does not adsorb to the column and a
total analyte fraction comprising the free analyte fraction
and the bound analyte fraction passes through the column,
applying a Series of Standards to the affinity column wherein
each Standard applied comprises a known concentration of
the same analyte present in the Sample, the column Separat
ing each of the Standards into a free fraction and a bound

starting mixture that contained 4.56x10 M HSA and
1.1x10 MS-warfarin at 25°C. An equilibrium constant of
3.4x10M was used to determine the initial amount of free
warfarin in this sample. A first-order rate constant of 0.14s'

fraction in the millisecond time domain wherein the free
fraction is adsorbed to the column and the bound fraction

passes through the column, applying the Same Series of

Standards set forth in (c) to an inert control column wherein

the free analyte fraction does not adsorb to the column and
a total analyte fraction comprising the free analyte fraction
and the bound analyte fraction passes through the column,
detection of Signal from the bound analyte fraction of the

was used to describe the dissociation of S-warfarin from
HSA
15

column and (b) an anti-warfarin immunoaffinity column at a
flow rate of 3.0 mL/min (effective column residence time, 60
ms). Other experimental conditions are provided in the

Sample in (a) above, detection of signal from the total
analyte fraction of the sample in (b) above, detection of
Signal from the bound fraction of the Standard in (c) above,

Materials and Methods of the Example section.
FIG. 6 depicts a Schematic of a chromatographic System
for the extraction and measurement of free and protein
bound warfarin. Details on the construction of this system
can be found in the Materials and Methods of the Example

detection of Signal from the total analyte fraction of the

Standard in (d) above, generating a calibration curve based
upon the signal detected in (g) above, the curve comprising
a graph of the bound concentration of analyte present in each
Standard versus the Signal detected for each concentration,
generating a calibration curve based upon the Signal detected

FIG. 5 depicts chromatograms for the injection of a 20 u,

sample of 8x107M R-warfarin onto (a) a diol-bonded silica

25

Section.

FIG. 7 depicts a chromatogram for separation of HSA
from R-warfarin after the passage of these compounds as a
mixture through an anti-warfarin immunoaffinity microcol

in (h) above, the curve comprising a graph of the total
concentration of analyte present in each Standard Versus the
Signal detected for each concentration, determining the
bound analyte fraction in the Samples by comparing the

umn. The initial sample contained 1.1x10 M R-warfarin
and 4.5x10-5 MHSA. Other conditions are provided in the

Signal in (e) above with the calibration curve in (i) above,

determining the total analyte fraction in the Samples by

teXt.

comparing the Signal in (f) above with the calibration curve
in () above, and determining the concentration of the free

FIG. 8 depicts simulated extraction of free warfarin from
a mixture of R-warfarin and HSA. The sample and column
conditions used in generating this plot were the same as
those that were present for the experimental results in FIG.

analyte fraction present in the Sample by Subtracting the

bound analyte fraction in (k) above from the total analyte
fraction in (1) above.
Still another aspect of the invention provides a method to
determine the concentration of a free analyte fraction in a
Sample, the Sample comprising a bound analyte fraction and
the free analyte fraction, the method comprising applying
the Sample to an affinity column wherein the column Sepa
rates the free analyte fraction from the Sample in the
millisecond time domain, detection of Signal from the free
analyte fraction Separated from the Sample and comparing

the signal detected in (b) to a standard thereby determining

35

7. The Solid bottom line indicates the relative amount of free
warfarin that was extracted in the absence of HSA. The Solid

top line shows the amount of warfarin that was extracted
from warfarin/HSA mixtures when the bound warfarin was
40

extracted warfarin was identical to the amount of free

warfarin in the injected Samples. These Simulations were
45

number of injections which were used to apply a fixed
amount of an immobilized hemoglobin Support to a 2.1 mm

and 0.4 s'

for the interactions of

column binding capacity of 5x10' mol and a second-order
50

association rate constant of 1x10 M S '.

Abbreviations and Definitions

To facilitate understanding of the invention, a number of
terms and abbreviations as used herein are defined below:
55

60

with an inner diameter of 1 mm or 4 mm gives Similar results
but with the vertical position of-the lines in this graph being
lowered or raised by 4-fold, respectively.
FIG. 3 depicts the reproducibility of stationary phase
content in a Sandwich microcolumn as a function of the

S

R-warfarin with HSA at 25 C. The adsorption of warfarin
to the immunoaffinity column was described by using a

BRIEF DESCRIPTION OF THE DRAWINGS

porosity of 0.80 within the column (i.e., 80% of the column
Volume is occupied by the mobile phase). Using a column

based on association and dissociation rate constants of

1x10 M

the concentration of free analyte present in the sample.
These and other features, aspects, and advantages of the
present invention will become better understood with regard
to the following description, appended claims and accom
panying figures where:
FIG. 1 depicts a drawing of a typical microcolumn that
may be employed in the method of the invention.
FIG. 2 depicts change in column Void time with column
length and solvent flow rate for 2 mm ID HPLC columns
packed with porous Silica. These results assume an overall

allowed to dissociate from and rebind to HSA as the sample
passed through the column. The dashed line is shown for
reference and represents a case in which the amount of
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“Analyte' or “Target Analyte” are used interchangeably
herein, and shall mean the component of the Sample that
binds to the binding agent present in the active layer of the
microcolumn. The analyte will typically comprise the free
fraction of a drug, hormone, toxin, metal ion, fatty acid,
bilirubin or any other endogenous or exogenous compound.
Additionally, the analyte may also comprise any other
inorganic or organic compound capable of being Separated
from the Sample, as described herein.
“Binding Agent', as utilized herein, shall mean the agent
in the active layer capable of Selectively binding the target
analyte.
“Binding Compound”, as utilized herein, shall mean the
compound that the bound fraction binds. Typically, the
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binding compound comprises a protein, cell or any other
endogenous or exogenous compound.
“Bound Fraction” or “Bound Analyte Fraction” are used
interchangeably herein, and shall mean the portion of the
analyte which is bound to a binding compound.
“Free Fraction” or “Free Analyte Fraction” are used
interchangeably herein, and shall mean the portion of the
analyte which is not bound to a binding compound.
"Millisecond Time Domain', as utilized herein, shall

mean any amount of time less than one Second.
"Sandwich microcolumn', as utilized herein, Shall mean
an embodiment of the invention wherein the microcolumn

contains a top inert layer, a bottom inert layer and an active
layer between the two inert layers.
“Sample” or “Liquid” are used interchangeably herein
and shall mean the mixture applied to the microcolumn
containing the analyte. In addition to the analyte, the Sample
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(liquid) generally also contains a loading buffer. Any loading
buffer may be employed to the extent that the buffer does not
interfere with the Separation process. The Sample may
comprise any mixture with an analyte. Typically, however,
the Sample will be comprised of a biological fluid Such as
blood, plasma, urine, cerebroSpinal fluid, tissue samples, or

FIG. 2 (plot derived by calculation), only columns with

intracellular fluid.

“Uniform Manner”, as utilized herein, shall mean loading
the layers of the microcolumn in a manner Such that these
layerS have a Substantially equal distribution of Support in
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both a horizontal and vertical direction.
BSA=Bovine Serum Albumin

FPLC=Fast-Protein Liquid Chromatography
HPLC=High-Performance Liquid Chromatography
Description of the Preferred Embodiments
Many compounds, as Stated above, exist in two distinct
35

compounds and 2) a fraction that is non-bound, or free, in
Solution. The free and bound fractions are present in a
dynamic State, in which Solutes in one State are continually
eXchanging with those in the other. Applicants have discov
ered a method to accurately determine the free analyte
fraction of a Sample comprising a free analyte fraction and
a bound analyte fraction. The method of the present inven
tion employs the use of affinity microcolumns to extract the
free fraction of an analyte from the Sample in the millisecond
time domain. The capability of extracting the free fraction in
this time domain allows the free fraction to be separated
without impacting the equilibrium between the free and
bound fractions. Applicants discovery, accordingly, circum
vents a major problem associated with the long Separation
times that plague current detection techniques. Upon its
Separation, the concentration of the free fraction is then
determined employing Standard analytical methods.
I. Affinity Microcolumn Design and Construction
The method of the present invention employs the use of
a microcolumn to Separate the free fraction of an analyte
from the Sample in the millisecond time domain. AS utilized
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In addition to rapid extraction of the free fraction, an
additional salient feature is the ability of the active layer to
bind the target analyte with both a high degree of Selectivity
and with a relatively high binding affinity. The active layer,
therefore, typically is comprised of Support particles deriva
tized with any binding agent possessing Selectivity and
having a high binding affinity for the target analyte.

Preferably, such binding affinity is from about 10° to about
10 M' or greater. In a preferred embodiment, the binding

agents are antibodies raised against the target analyte. The
antibodies can be either monoclonal or polyclonal.
However, monoclonal antibodies are generally employed in
applications where a higher degree of Selectivity is desired
and polyclonals are more typically utilized in applications
where a higher degree of binding 35 affinity is desired.
Examples of other Suitable binding agents include nucleic
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acid ligands (e.g. aptamers), Synthetic molecular imprints,
antibody fragments (e.g. Fab fragments), antibody related
molecules (e.g. chimeras or F, chain fragments), and
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recombinant proteins that act as antibody mimics. The
binding agent, once Selected, may be isolated in accordance
with any generally known method.
The binding agent can be derivatized to the Support
particles by any method generally known in the art.
However, the method preferably immobilizes the binding
agent to the Support particle in a manner Such that a

Second ends 6 of the microcolumn 1. However, the micro

column 1 may comprise any number of different shapes, all
of which are embodiments of the present invention. The
retaining means 5,6 typically comprises a mesh or Small

and preferably, is not less than approximately 60 microns in
thickness. Applicants have found that active layers with
these dimensions, depending upon the Specific Sample
applied, are generally capable of extracting an analyte in
about 1 to about 500 milliseconds. And, more preferably, in
less than about 200 milliseconds.

herein, the terms “microcolumn” or “column” are used

interchangeably and FIG. 1 depicts a typical microcolumn
that may be employed in the method of the invention. As
shown in FIG. 1, the microcolumn 1 generally has a tubular
configuration with a first end 2, a Second end 3, a passage
way 4 there between, and a retaining means at the first 5 and

active layer lengths in the range of about 100 microns to
about 1 millimeter allow Separation in the millisecond time
domain when employing standard HPLC flow rates of about
0.1 to about 1.0 mL/min. Accordingly, to achieve Separation
in this time range, the microcolumns employed generally
comprise an active layer that may be less than about 10
microns in thickness. Typically, however, the active layer is

from about 10 microns to about 1.1 millimeters in thickness

forms as they pass through the blood stream: 1) a fraction

that is non-covalently bound to proteins or other binding

pore material that acts to hold the Support particles within
the column while allowing fluid flow there through. The
microcolumn 1 may also contain end fittings at the first 7 and
Second 8 ends of the microcolumn 1 used to connect the
column to the chromatographic System. The microcolumn 1
comprises a thin active layer 9 to facilitate Separation of the
analyte from the Sample in the millisecond time Scale and
typically a Single inert layer in one embodiment, to Several
inert layers in additional embodiments. FIG. 1 illustrates an
embodiment with a top inert layer 10 and a bottom inert
layer 11.
A Salient feature of the current invention is the capability
of removing a significant amount of the free fraction of a
particular analyte from a Sample without release of the
analyte from its protein-bound fraction. In order to accom
plish this task, as delineated above, the extraction process is
preferably accomplished in the millisecond time domain.
The microcolumn design described herein is particularly
Suitable for this application because, due in part to its
relatively thin active layer, it can extract the free fraction
within this time range. AS utilized herein, “length' of a layer
means the thickness or width of the layer. As illustrated by
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relatively high percent of the binding agent is active (i.e.
binds the target analyte) after the immobilization process.

Suitable immobilization methods for protein ligands, for
example, include the Schiff base method and the carbonyl
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diimidazole method. The Schiff base method is generally
employed when immobilizing the binding agent through free
amine groups.
However, when the binding agent comprises antibodies,
applicants have found that a more preferred approach is
immobilization through the antibodies carbohydrate region
because this generally results in an active layer with a higher
number of active binding Sites compared to when immobi
lization is performed through free amine groups. Any
method known in the art for immobilization via carbohy
drate regions may be employed.
Additionally, the Overall binding capacity of the micro
column is also an important feature because it impacts both
the time and efficiency of extraction by the active layer. The
binding capacity of the column, in part, is determined by the
number of active binding siteS present in the active layer.
Preferably, the minimum number of active binding sites in
the column comprises a ratio of active binding Sites to free
analyte not leSS than about 1:1, and even more preferably,
not less than about 10:1. However, still more preferably,
Support particles in the active layer will be derivatized with
the maximum concentration of active binding agent achiev
able So that the column has the largest binding capacity
possible.
The active layer, additionally, may comprise a number of
different Support particles. The Support particles, as detailed
above, function primarily as a Surface to immobilize the
binding agent. The diameter of the particle, however, is an
important feature that should be considered because it
impacts both the length of the active layer and the amount
of binding agent that may be immobilized in the active layer
(i.e. binding capacity of the column). Preferably, the particle
Size is Smaller than the length of the desired active layer.
Applicants have found that a preferred particle diameter is
less than about 10 times to about 20 times the length of the
active layer because particles within this size range facilitate
uniform packing of the layer by allowing Small packing
defects to average out and produce a more uniform packing
croSS-Section for the Support. In addition, the Support par
ticles should be able to tolerate the flow rates and pressures
needed in order to obtain the desired Sample contact time
with the active layer. The properties that affect the pressure
and flow rate that may be tolerated by the Support particles
include the diameter of the particle, the particle's shape and
the porosity of the particles. Suitable Support particles
include porous or nonporous glass, Silica and other inorganic
Supports (e.g., alumina or Zirconia), carbohydrate-based
Supports (e.g.,beaded agarose), and polymeric Supports (e.g.,
polymethacryltate or polystyrene based resins); however,
one generally skilled in the art of chromatography can Select
other appropriate Support particles.
The microcolumn may comprise a single inert layer or
Several inert layers, depending upon the application.
However, common features shared by all inert layers, irre
spective of their number or position within the
microcolumn, is that they typically should have no Substan
tial interaction with the target analyte, and should preferably
be mechanically stable under the flow rate and pressures
employed during the Separation process. Preferable materi
als for construction of the inert layer include diol-bonded
Silica, diol-bonded glass beads, agarose beads, hydroxylated
perfusion media, and glycol coated perfusion media. The
various inert layerS may be constructed from the same
Support particles or different Support particles. However, it is
usually preferred for the Sake of convenience in loading the
microcolumn that the inert layerS comprise the same Support
particles.

8
The layers in the microcolumn may comprise either an
active layer alone, or an active layer and a single inert layer

on top of the active layer (wherein the active layer is in
communication with the Second end retaining means) Such

that liquid first passes through the inert layer and then passes
through the active layer. The utilization of a single inert layer
in this manner is especially Suitable for applications where

the liquid (containing the sample) is to be applied in only a
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Single direction to the active layer and the column. The inert
layer in this application preferably occupies the entire length
of the microcolumn between the beginning of the first end of
the microcolumn to the beginning of the active layer So that
the entire microcolumn is filled with Support particles.
Applicants have found that having the entire microcolumn
filled with Support particles increases both the Speed and
efficiency of Separation. Additionally, the inert layer in this
application also preferably acts to distribute the injected
Sample evenly acroSS the diameter of the column before the
Sample reaches the active layer. This allows for a more
uniform application of the Sample to the relatively thin
active layer.
The layers in the microcolumn may also comprise an
active layer Sandwiched between a top and a bottom inert
layer. As utilized herein, the term “top inert layer” shall
mean the layer that liquid first passes through prior to
reaching the active layer and “bottom inert layer shall mean
the layer where liquid passes after it exits the active layer.
The microcolumn preferably comprises both a top and
bottom inert layer for applications where liquid is to be
applied in two directions to the active layer and the column.
At any given time, the flow of liquid through the column is
generally only in a single direction. However, it is Some
times preferable to alternate the flow of liquid through the
column in order to help wash out any impurities that may
have built up at the top of the column during the application
of liquid. The top inert layer in this application Serves the
Same role as discussed above for the application employing
a single inert layer e.g. more efficient Separation. However,
applicants have found that it is preferable to include the
bottom inert layer, even in applications where fluid flow is
in only a single direction, because its inclusion increases the
useful life of the active layer by preventing loSS of Support
particles.
The thickness of the inert layerS is not a critical feature
and does not affect the time needed to Separate the free
fraction of an analyte from the sample. In general, as Stated
above, the top inert layer is preferably the length that
remains between the beginning of the column and the
beginning of the active layer. And, the bottom inert layer, if
it is present, is generally from about 1 to about 5 times the
length of the active layer. Typically, the top inert layer is
thicker than the bottom inert layer.
The choice of a particular type of housing for the micro
column is also not a critical facet. The microcolumn
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housing, however, preferably employs components made of
materials that are Substantially inert to biological fluids and
in particular, Substantially inert to the analyte So as not to
interfere with the Separation process. Accordingly, any mate
rial that is Substantially inert may be employed to construct
the microcolumn. Suitable materials include Stainless Steel,

polypropylene, certain plastics and fused Silica.

The dimensions of the microcolumn are also not a critical
65

feature. Any size of microcolumn may be utilized to the
extent that the total column length is preferably greater than
the length of the active layer. The total column length and
diameter also preferably allow the use of sufficiently fast
flow rates and pressures to achieve the desired contact time

US 6,720,193 B2
9

10

between the sample and the active layer. Preferably, the

appropriate slurry density needed to achieve a layer having
a particular thickneSS when employing a Specific number of
injections.
The desired slurry density, once Selected, is preferably
maintained throughout column injection in order to facilitate
uniform layer packing. To maintain consistent Slurry density,
the Slurry typically undergoes Shaking between injections to
ensure that the Support particles are uniformly distributed in
the slurry. It is also preferable to monitor the turbidity of the
Slurry at a wavelength of approximately 800 nm to ensure
the amount of Support particles per milliliter remains con
Stant. Furthermore, typically the Slurry density is calculated
at numerous points during injection by comparison to Slur
ries of known density employing the same Support particles.
Applicants have also found, in addition to loading the
Support particles by a plurality of injections, that varying the
flow rate and pressure during column loading also serves to
provide a more uniform and thin active layer. In a particu
larly preferred application, the pressure and flow rate are
increased for a short period of time near the beginning and

microcolumn has an internal diameter of about 50 microns

to about 2 centimeters and a length of about 0.2 millimeters
to about 2 centimeters. In a particularly preferred
embodiment, the microcolumn has an internal diameter of

about 0.5 to about 2.1 millimeters and a length of about 1
millimeter to about 2 centimeters.

Applicants have found that thin active layerS may pref
erentially be obtained by loading the Support particles com
prising the layer into the microcolumn via a plurality of

injections, as described in detail below (e.g. see FIG.3). The

normal method of loading a column, applying the Support
particles in one application to the column with the amount
of Support particles being in exceSS of that which is needed
to fill the column, is Sufficient for Standard Size chromatog
raphy columns because due to their size, reliable packing of
the Support particles may be achieved.
Applicants, however, have found that loading the Support
particles in a Single injection, for columns with dimensions
described herein, generally does not result in an active layer
capable of consistently achieving Separation of an analyte
from a Sample in the millisecond time Scale.
Accordingly, the layers are preferably loaded into the
column by a plurality of injections of Slurry comprising the
Support particles. The Slurry may be injected into the column
employing any apparatus generally known for injecting a
Slurry into a column, for example, a closed-loop Sample
application System with either a manual injection valve or an
automatic injection System may be utilized. The slurry, in
addition to Support particles, also preferably comprises a
packing Solvent or buffer. The packing Solvent employed to
load the slurry into the column is not a critical feature;
however, the solvent preferably will not harm the binding
agent present in the active layer. One skilled in the art of
chromatography can readily Select both an appropriate appa
ratus to inject the slurry and appropriate packing Solvents.
Applicants have also found, as illustrated by FIG. 3,
employing a larger number of injections and leSS Support per
injection, achieves a more controlled delivery of Support
particles because Statistical variations that occur during the
delivery of Small amounts of Support particles to the column
are averaged out. This is particularly true as layer thickneSS
decreases. Uniform packing of Support particles in the
layers, especially the active layer, is preferable because it
provides more reproducible results for injected Samples by
allowing parts of the Sample that are injected at different
locations along the diameter of the column to achieve
consistent Sample contact times with the active layer.
Accordingly, the number of injections to introduce a layer
into the column is generally from about 10 to about 100.
More preferably, the number of injections to introduce a
layer is from about 30 to about 40 when the layer length is
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end of the loading of each layer (as illustrated in Table 1).
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This increased pressure and flow rate facilitates compression
of the layer and distributes the Support particles within the
layer evenly acroSS the diameter of the column. In a typical
column loading procedure, for example, the flow rate of
slurry injection into the column is between about 3 mL/min
and about 5 mL/min, with the higher flow rate occurring
generally at the beginning and end of the loading of each
layer.
Additionally, pressure during column loading is typically
maintained between about 2000 and about 4000 psi, with a
higher pressure preferably occurring at the beginning and
end of the loading of each layer. The particular flow rates
and preSSures utilized to load each layer of the column is not
a critical feature and accordingly, may be varied Signifi
cantly from the general examples provided hereindepending
upon the particular application.
Table 1 Sets forth a general procedure for loading a 1.0 cm
immunoaffinity microcolumn comprising an active layer
between a top and bottom inert layer. The procedure set forth
in Table 1 is for illustrative purposes only and shall not be
construed to limit the Scope of the present invention as
described in greater detail herein.

45

TABLE 1.

1
50

2

from about 100 to about 500 microns, and is from about 60

to about 80 injections when the layer length is from about 60
to about 100 microns in length.
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The slurry density (milligrams of Support particles per
milliliter of packing Solvent), or amount of Support particle

applied to the column per injection, will vary greatly
depending upon the desired thickness of the layer.
Typically, however, the slurry density will be from about
0.1 to about 20 milligrams of support particles per milliliter
of packing Solvent and more preferably, will be from about
1 to about 5 milligrams of Support particles per milliliter of

packing Solvent. In general, the inert layer(s) and active
layer are loaded at approximately the same Slurry density.
One of ordinary skill in the art can readily determine the

60
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General Procedure for Preparing a Microcolumn
Assemble column fittings on the second end of the
microcolumn (and retaining means) and attach the
microcolumn to the packing apparatus;
Make two particle support slurries in the packing
solvent, one consisting of inert support particles, and
the other containing the active support particles. For
an immunoaffinity microcolumn, the packing solvent
employed may be pH 7.0, 0.10 M potassium phosphate
buffer and the slurry of the inert support particles
typically may contain a diol-bonded material (e.g. 2
mg/mL diol-bonded silica). The second slurry contains
the immunoaffinity support particles at a concentration
that is determined by utilizing equation 2 or any other
generally known method (as set-forth in the examples
below) and the desired thickness of the final active
layer
Begin flow of the packing solvent through the column.
This is generally done at a rate of approximately 3
mL/min for immunoaffinity microcolumns, but is not
critical. Make approximately five injections (at 150
uL per injection for a 1.0 cm long column) of the inert
support slurry, followed by an increase in flow rate to
approximately 5 mL/min for approximately 5 minutes
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entails applying a Series of Standards to the same affinity
column. "Standard” as utilized herein, shall mean a mixture

TABLE 1-continued

4

5

that contains a known concentration of the analyte. The
Standard will preferably comprise the same analyte as is
being detected in the Sample and depending upon the
embodiment of the invention, may also comprise a binding
compound. “Series of Standards” as utilized herein, shall
mean applying from about two to about five Standards with
different analyte concentrations to the column. In another
embodiment of the invention, the Series of Standards may be
determined without applying the Standards to the column for
each application of the method, Such as when the calibration

General Procedure for Preparing a Microcolumn
Return the flow rate to approximately 3 mL/min and make
the required number of injections of the active layer
(per equation 2 or any other generally known method).
After making these injections, increase the flow rate
to approximately 5 mL/min for approximately 5 minutes
Return the flow rate to approximately 3 mL/min and make
enough injections of the inert support slurry to fill
the remainder of the column bed

6.

After the column bed has been filled, increase the

column backpressure to the desired level, typically
about 3000 to about 4000 psi. Allow the column to
equilibrate at this pressure for approximately 10
minutes. Gradually release the pressure. Remove the
column from the packing apparatus and place a frit
(retaining means) and end fitting onto the open end of
the column. The column is now ready for use

The microcolumn, in addition to its relatively thin active
layer, is also generally able to tolerate flow rates and
preSSures during Sample injection that are capable of achiev
ing the desired Sample contact time with the active layer. The
flow rate and preSSure depends not only on the Support
particles employed in layer construction, but also on the
column diameter and upper pressure limit that can be
tolerated by the chromatographic System. In general, any
flow rate and preSSure necessary to achieve the desired
residence time and tolerated by the chromatographic System
employed is within the Scope of the present invention.
Typically, however, the microcolumns may be Subjected to

curve has been determined previously (from analysis of the
same standard in an earlier test) or when the Standard comes
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In accordance with the method of the invention, the
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flow rates of between about 0.01 to about 9.0 mL/min and

pressures between about 10 to about 6000 psi. More
preferably, the pressure is between about 100 to about 1500
psi.
II. Determination of the Free Analyte Fraction
Encompassed in the method of the invention is a means to
determine the concentration of the free analyte fraction in a
ample comprising a free fraction and a bound fraction. The
method entails generating a calibration curve comprising
data obtained by analyzing a Series of Standards containing
a known concentration of the same analyte present in the
Sample. The concentration of the free analyte present in the
Sample, as described in detail below, is then determined by
comparison to the calibration curve.
Applicants have found that accurately determining the
concentration of free analyte in a Sample preferably involves
the rapid and Selective extraction of this fraction from the
Sample before significant release from its bound fraction.
Additionally, applicants have found that this release gener
ally occurs within a few Seconds, particularly when the
analyte binds a Serum protein or other binding compound,
Such as HSA or alpha 1-acid glycoprotein. The affinity
microcolumns described in detail above, therefore, are par
ticularly Suited for the method of the invention because they
are capable of Selectively extracting the free fraction within
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achieve a high rate of binding and generally include: 1) an

active binding agent in the column that is 35 capable of

40

equal to or greater than the concentration of free analyte

injected into the column (as discussed above), and 4) the

45

residence time is typically optimized Such that the time is
preferably long enough that a Significant concentration of
the free analyte binds to the column and yet, short enough
in duration to prevent significant dissociation from the
bound fraction. The Sample and Standards may be applied to
the column by any means generally known in the art, Such
as through the use of an injection valve or autoninjector
System.

50
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the column.

In addition to the parameters Set forth above impacting
binding capacity, a number of operating conditions
employed during Sample and Standard injection onto the
column are also preferably optimized. One Such operating
parameter is Selection of the loading and elution buffers. The
buffers selected preferably mimic the pH and solvent con
ditions of the Sample to ensure that the equilibrium between
the free and bound fractions is not disrupted. For example,
when a biological Sample is being analyzed, any physiologi
cal buffer, Such as phosphate buffer, may be employed. And,
the buffer typically will have a pH of approximately 7.2 to

about 7.4 (pH of blood, serum or plasma). The temperature

Accordingly, the method of the invention encompasses

applying a sample to the affinity column (described in detail
above) under conditions sufficient to bind the free analyte

fraction without Significant interference from its bound
fraction, which passes through the column without adsorb
ing. The method, irrespective of the embodiment, also

concentration of free analyte present in each Standard is
determined. This concentration may be determined based
upon mass or Volume measurements in which a known
concentration of pure analyte is weighed and placed into a
known volume of Solution. Equally, a known volume of
solution may be diluted or combined with another solution
to prepare the final Standard Solution. In addition to these
methods, the concentration may be determined by any
means generally known in the art.
Additionally, the Sample and Standard, irrespective of the
embodiment of the invention, are preferably injected onto
the column under conditions that optimize a rapid and
Selective binding of the free analyte to the column. A number
of conditions may impact the degree of free analyte binding
to the column. These conditions are preferably optimized to

binding the free analyte, 2) Solution conditions (as set forth
in more detail below) preferably favorable for binding to
occur, 3) the binding capacity of the column is preferably

the millisecond time domain. The bound fraction, on the

other hand, does not bind to the affinity column and is
therefore present in the liquid fraction that passes through

as a part of a kit. The series of standards will preferably
contain concentrations of free analyte that are Substantially
comparable to the concentration of free analyte expected to
be present in the Sample.
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during injection of Standard/sample onto the column is also
important. Again, the temperature will preferably mimic the
natural temperature of the Sample to avoid disrupting the
binding properties of proteins in the Sample prior to their
application to the affinity column. Additionally, applicants
have found that flow rate during Sample injection can
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computer program generally known in the art for linear or
non-linear regression.
The concentration of the free fraction present in the
Sample can then be readily determined utilizing the calibra
tion curve delineated above by Simply comparing the Signal
detected from the free analyte fraction Separated from the
Sample with the array of Signals depicted on the calibration
curve. This direct comparison is possible because the curve
depicts the Signal for known concentrations of the free

13
dramatically impact both extraction efficiency and dissocia
tion of analyte from the bound fraction. Typically higher
flow rates result in leSS dissociation, while slower flow rates

increase extraction efficiency. Therefore, an intermediate
flow rate is preferably employed during column injection
and one generally skilled in the art of chromatography can
readily determine this rate, which will vary depending upon
the particular application. Typically, however, the flow rate
is from about 0.1 to about 10.0 ml/min, and even more

preferably, the flow rate is from about 0.5 to about 1.5

fraction (generated from the Series of Standards). Therefore,

ml/min.

Accordingly, in one embodiment of the invention the
concentration of free analyte present in the Sample is deter
mined by analyzing data from a Series of Standards com
prising known concentrations of the same free analyte
present in the Sample without the presence of any binding
compounds. In this embodiment, therefore, the concentra
tion of the free fraction is determined by directly analyzing

the concentration of the free fraction of the Sample may be
determined by comparing its signal to signal depicted in the
calibration curve for the standards with known free analyte

concentrations.
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data from the free fraction of the series of standards (“Direct
Method”). The sample, as detailed above, is applied to the

Direct Method detailed above, the concentration of the free

column employing the same operating parameters as with
injection of Standard onto the column. The column Separates
the Sample and Series of Standards into a free fraction and a

fraction of the Sample is determined by analyzing data from

the bound fraction and a total fraction (described below)
from the series of standards (“Indirect Method”). In this

bound fraction in the millisecond time domain. AS detailed

above, the free fraction of both the standard and sample is
adsorbed to the column, while the bound fraction passes
through the column.
The free analyte fraction of both the standard and sample
isolated by the column is typically then detected as a signal
by any means generally known in the art of analytical
chemistry. “Signal” as utilized herein, shall mean the chemi
cal or physical response that allows the analyte to be

detected (in either the standard or Sample). The signal can
either be generated by the analyte itself (e.g. see detection of
warfarin in the Example below) or generated by another
compound that is linked to the analyte (e.g. the use of a
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domain. Additionally, the free fraction of both the standard
and sample is adsorbed to the column while the bound
fraction passes through the column. In the Indirect Method,
in contrast to the Direct method, the bound fraction of both
35

to be detected). In addition, the signal is specific to the

on-line or off-line method. An "on-line” method, as utilized
herein, shall mean a method in which there is a direct

40
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coupling between isolation of the free fraction (via affinity
chromatography) and its detection Such that the isolated
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mean a method in which the isolated fraction is collected and

then manually transferred to the detection mechanism. Suit
able detection methods include immunoassay, mass
Spectrometry, gas chromatography, and detection based
upon ultraViolet absorbance, fluorescence detectors, and
electrochemical detectors. Preferably, however, the detec
tion technique utilized will comprise an on-line method with
direct detection in order to facilitate efficiency of Such
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detection.

The calibration curve can then be generated after the
isolation and Subsequent detection of Signal, as detailed

the sample and Series of Standards is retained for further
analysis in the next Step of the method.
However, also in contrast to the Direct Method, the

Indirect method employs the use of an additional inert
control column. In this embodiment, the same Sample and
Series of Standards applied to the affinity column described
above are applied to an inert control column. The inert
control column comprises a column constructed in all details
like the affinity column discussed above except that the
Support particles in its active layer are not derivatized with
a binding agent. For example, the inert control column and
affinity column employed in this embodiment are the same
size, are constructed from the same materials, and are

operated under the same parameters (i.e. pressure and flow
rate). However, because the inert control column is not

fraction is automatically transferred to the detection mecha
nism through an interface that connects the two Systems. An
“off-line” method, on the other-hand, as utilized herein, shall

embodiment, Similar to the embodiment delineated above,

the Sample and Series of Standards are applied to the affinity
column employing the same operating parameters. The
column Separates the Sample and Series of Standards into a
free fraction and a bound fraction in the millisecond time

labeled analog of an analyte to allow the unlabeled analyte

particular detection method employed. The choice of a
particular detection method is not critical. However, the
detection method employed is preferably the same for both
the Standard and Sample in order to generate a reliable
calibration curve. Detection may be performed by either an

In yet another embodiment, the concentration of the free
analyte fraction of the Sample is determined by analyzing
data from a Series of Standards comprising known concen
trations of the same free analyte present in the Sample and
a binding compound. In this embodiment, in contrast to the
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derivatized with binding agent, the free analyte fraction is
not separated from either the Sample or Series of Standards.
Instead, a total analyte fraction comprising the bound frac
tion and free fraction pass through the column. The total
fraction is retained from both the Sample and Series of
Standards for further analysis in the next Step of the method.
The signal of the bound fraction of both the sample and
Series of Standards is then detected by any means generally
known in the art of analytical chemistry, as described in
detail above for the Direct Method. In addition, the signal of
the total fraction of both the Sample and Series of Standards
is also detected in accordance with the procedures described
above for the Direct Method.

above, of the Standard with known concentrations of free

In contrast to the Direct Method, the Indirect Method

with a spreadsheet (e.g. Lotus or Excel) or by employing any

entails generating two calibration curves. The first calibra
tion curve comprises a graph depicting the concentration of
analyte present in the bound fraction for each Standard
Versus the Signal detected for each concentration. The Sec
ond calibration curve comprises a graph depicting the con

analyte. The calibration curve comprises a graph depicting
the concentration of free analyte present in each Standard
Versus the Signal detected for each concentration.
Additionally, the plot can be generated either manually,

65
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centration of analyte present in the total fraction for each
Standard versus the Signal detected for each concentration.
AS described above, the calibration curves can be generated

R-(+)- and S-(-)-warfarin, which are given as a racemic

attacks and Strokes. It exists in two enantiomeric forms,

mixture. Both forms have pharmacological activity, but
S-warfarin is Several times more potent than the

either manually, with a spreadsheet (e.g. Lotus or Excel) or

by employing any computer program generally known in the
art for linear or non-linear regression.

R-enantiomer. In the circulation, R- and S-warfarin exist

mainly in their bound forms, with most of this binding
occurring with the protein HSA. Because of warfarin's
pharmaceutical significance, binding affinity for HSA, and
Stereochemistry, it is an excellent model to illustrate the
broad applicability of the method of the current invention.

In accordance with the method of the invention, the

concentration of the free analyte fraction present in the
Sample can then be determined utilizing the two calibration
curves described above. The concentration of the bound

analyte fraction present in the Sample can readily be deter
mined by comparing the Signal detected for the bound
fraction of the Sample with the calibration curve depicting
the signal detected from the bound fraction of the series of
Standards with known analyte concentrations. The concen
tration of the total fraction present in the Sample can also be
readily determined by comparing the Signal detected for the
total fraction present in the sample with the calibration curve
depicting the Signal detected from the total fraction of the
Series of Standards with known analyte concentrations.
Finally, per this method, the concentration of free analyte
present in the Sample can be determined by Simply Subtract
ing the concentration of the bound fraction present in the
Sample from the concentration of the total fraction present in
the Sample.
The methods of the present invention may be employed to
determine the free analyte fraction of any Sample comprising

Materials and Methods

Reagents. The R- and S-warfarin were donated by Dupont

Pharmaceuticals (Wilmington, Del.). The polyclonal anti
warfarin antibodies were from Accurate Chemical
15

Mallia, A. K., Gartner, F. H.; Provenzano, M. D.; Fujimoto,
E. K., Goeke, N. M., Olson, B. J., Klenk, D. C. Anal.
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a bound and free fraction, to the extent that the free fraction

is capable of being Separated from the Sample, as described
herein. A typical application for the method, however, is the
clinical analysis of the free fraction of a hormone, drug and
other endogenous or exogenous agents present in biological
Samples. The method may also be employed for the phar
maceutical analysis of free drug levels or drug metabolite
levels in biological Samples. Equally, the method may be
employed in toxicology Studies to quantify the free fraction
of organic compounds and/or inorganic compounds present
in a Sample. In a research Setting, the method may be utilized
to Study the mechanism of protein binding processes.
The detailed description set-forth above is provided to aid
those skilled in the art in practicing the present invention.
Even So, this detailed description should not be construed to
unduly limit the present invention as modifications and
variation in the embodiments discussed herein can be made

by those of ordinary skill in the art without departing from
the Spirit or Scope of the present inventive discovery.
All publications, patents, patent applications and other
references cited in this application are herein incorporated
by reference in their entirety as if each individual
publication, patent, patent application or other reference
were specifically and individually indicated to be incorpo
rated by reference.

EXAMPLES
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The examples illustrate the ability of the method of the
present invention to detect the free fraction of warfarin from
a Sample comprising warfarin and human Serum albumin

(“HSA'). Warfarin is one example of a drug which has

Significant binding in blood, and is a common anticoagulant
used in humans for the treatment and prevention of heart

Biochem. 1985, 150, 76.) were from Pierce (Rockford, Ill.).
HSA (Cohn fraction V, 99% pure, fatty acid free) and rabbit
immunoglobulin G (IgG) were purchased from Sigma (St.
Louis, Mo.). All other chemicals were reagent-grade or
better. All aqueous Solutions were prepared using deionized
water from a Nanopure water System (Barnstead, Dubuque,
Iowa).
Apparatus. Samples for the BCA protein assay were
analyzed using a Shimadzu UV160U absorbance spectro

Without further elaboration, it is believed that one skilled

in the art can, using the preceding description, utilize the
present invention to its fullest extent. The following pre
ferred Specific embodiments are, therefore, to be construed
as merely illustrative, and not limitative of the remainder of
the disclosure in any way whatsoever.

(Westbury, N.Y.). The HPLC-grade Nucleosil Si-500 and
Si-1000 silica (7 um particle size, 500 A and 1000 A pore
size) was obtained from Alltech (Deerfield, Ill.). The
7-amino-4-coumarin-3-acetyl hydrazide (AMCA
hydrazide) and reagents for the bicinchoninic acid (BCA)
protein assay (Smith, P. K.; Krohn, R.I.; Hermanson, G. T.;

photometer (Kyoto, Japan). Immunoaffinity columns were
packed using a modified N60 injection valve from Valco
(Houston, Tex.) and a CM3000 HPLC pump from LDC
Analytical (Riviera Beach, Fla.). The final chromatographic
System used in the analysis of free and bound warfarin
consisted of one anti-warfarin immunoaffinity microcolumn
(prepared as described later) in Series with two 5 cmx2.1
mm ID Pinkerton GFF II internal surface reversed-phase
(ISRP) columns from Regis Technologies (Morton Grove,
Ill.). Detection in the chromatographic System was per
formed by a Shimadzu RF-535 fluorescence monitor.
Samples were injected by an AS3000 autosampler from
Thermoseparations (Schaumberg, Ill.). The application and
elution buffers for the immunoaffinity column were deliv
ered using PU-980 HPLC pumps from Jasco (St. Louis,
Mo.). A LABPro automated six-port valve from Rheodyne
(Cotati, Calif.) was used to switch between these buffers. An
organic modifier for displacement of the HSA-bound war
farin was introduced to the effluent of the immunoaffinity
column through the use of a post-column mixing tee and a
CM3200 pump from LDC Analytical. The chromatograms
were collected on a 300 MHZ Pentium computer from TCE
(Hoffman Estates, Ill.) with Winner-on-Windows software
from ThermoSeparations. The temperature of the System was
controlled using a VWRbrand 13L immersion circulating
water bath from VWR Scientific (West Chester, Pa.).
Preparation of Immunoextraction Column. Antibodies
were purified using AMCA-hydrazide as an affinity ligand.
AMCA is a coumarin derivative that is similar in structure
to warfarin. It was used here to isolate anti-warfarin anti

bodies from their corresponding antiserum. The AMCA
hydrazide was coupled to Nucleosil Si-1000 silica in a
manner Similar to that reported for the Synthesis of
65

dihydrazide-activated silica (Ruhn, P. F.; Garver, S.; Hage,
D. S. J. Chromatogr. A 1994, 669, 9.). The anti-warfarin
antibodies were isolated with this Support by incubating one
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milliliter of anti-warfarin antiserum with 300 mg of the
AMCA silica for two hours at room temperature. After 15
incubation, the Samples were centrifuged and the Superna
tant was removed. The Support was then washed with pH
2.5, 0.10M potassium phosphate buffer for 10 min, followed
by a Second centrifugation Step. This Second Supernatant

the warfarin in these samples were then compared to the
areas obtained for warfarin/HSA standards with the diol
column.

Computer Simulations. The simulations of warfarin
extraction and dissociation were performed on an IBM
compatible computer using programs written in Turbo C++

(containing purified anti-warfarin antibodies) was then

(Borland International, Scotts Valley, Calif.). This was

collected, adjusted to pH 7.0 with a small concentration of
1.0 M sodium hydroxide, and stored at 4 C. until further
Sc.

Diol-bonded Nucleosil Si-500 silica was prepared as

described previously (Ruhn, P. F.; Garver, S.; Hage, D. S.
J. Chromatogr. A 1994, 669, 9.). The diol coverage of this
Support was 127-4 (1 SD) umol/g of Silica, as determined in
replicate by an iodometric capillary electrophoresis assay.
The purified anti-warfarin antibodies were immobilized to

15

this diol-bonded silica by the Schiff base method (Larsson,
P-O. Methods Enzymol. 1984, 104, 2121). The protein

content of the resulting immunoaffinity Support was deter
mined by a BCA assay to be 2.05+0.05 mg antibodies/g

method (Margenau, H.; Mosely, G. M. The Mathematics of
Physics and Chemistry; Van Nostrand; Princeton, 1956.).

Silica (or 14 nmol/g), using rabbit IgG as the standard and
diol-bonded silica as the blank.

The anti-warfarin immunoaffinity Support was used to
pack a Sandwich microcolumn, as described herein. This
column had an inner diameter of 2.1 mm and a total length
of 1.0 cm, with a 1.1 mm portion containing the immunoaf
finity Support and the remainder containing an inert layer of
diol-bonded silica. The immunoaffinity layer was placed
within this column by making thirty-two 250 till injections
of a 0.3 mg/mL slurry of the anti-warfarin support in pH 7.0,
0.10 Mphosphate buffer. The remainder of the column was

25

that had adsorbed to the column was then calculated, thus

Chromatographic Studies. The extraction Studies were

performed by making 20 uL injections of 0.8-5x107 M

error of less than 0.2% in the calculated concentration of

warfarin at flow rates ranging from 0.5 to 3.0 mL/min. Five
replicate injections were made at each flow rate using
microcolumns that contained the immunoaffinity Support or
only diol-bonded Silica. The non-retained peaks observed
with the immunoaffinity column were compared to those

35

Seen on the diol column to determine the relative concen

40

Initial Selection of Conditions for Free Drug
Extractions

B.; Hage, D. S. Anal. Chem. 1994, 66, 3814 and Loun, B.;

45

information, it was possible to estimate the time needed to

mixture without having this fraction contain a significant
concentration of warfarin that had been released from its
50

diol microcolumn that was in series with two ISRP columns.

The samples in this study contained 0-3.5x10 M war
farin and 3 mg/mL (4.5x10 M) HSA in pH 7.0, 0.10 M

tion of HSA-bound warfarin. The same chromatographic
System was used to determine the concentration of free
warfarin in warfarin/HSA mixtures by replacing the diol
column with the immunoaffinity microcolumn. A Series of
twenty replicate injections were made in this experiment
using Samples that contained well-defined concentrations of
R- or S-warfarin and HSA. The non-retained peak areas for

Hage, D. S. Anal. Chem. 1996, 68, 1218.). Based on this

remove the free fraction of warfarin from a warfarin/HSA

mL/min.

was added at a flow rate of 0.2 mL/min to induce dissocia

Previous reports have measured the equilibrium and rate
constants for the binding and dissociation of R- and

S-warfarin with HSA under a variety of conditions (Loun,

regenerate for 10 min in the application buffer at 1.0

phosphate buffer. These Samples were injected at 1.0
mL/min in the presence of the pH 7.0 application buffer. A
Separate Solvent Stream was introduced directly after the
microcolumn using a three-way mixing tee. In the final
optimized System, this Second Solvent Stream contained
7.5% 1-propanol in pH 7.0, 0.10 M phosphate buffer and

retained analyte.
EXAMPLE 1.

with the elution buffer at 1.0 mL/min and was allowed to

The separation of HSA and HSA-bound warfarin was
studied by injecting 20 L of warfarin/HSA mixtures onto a

Flow through the column was simulated after each iteration
by taking the compounds that remained in the mobile phase
and moving these onto the next Slice. The process of
distributing and moving the analytes was repeated until all
of the analyte had either bound to the immobilized ligand or
had left the column. The relative concentration of analyte
providing the retained fraction. Convergence of these results
was tested by performing a Series of related Simulations in
which the column was divided into an increasing number of
Slices but with a decreasing concentration of time being used
per iteration in each Slice. This gave a maximum estimated

filled in a similar manner with diol-bonded Nucleosil 500.

tration of warfarin that had been removed by the immobi
lized antibodies. The application buffer in these studies was
pH 7.0, 0.10 M potassium phosphate and the elution buffer
was pH 2.5, 0.10 M potassium phosphate. Between
injections, the immunoaffinity column was washed for 5 min

accomplished by using a grid propagation algorithm that has
previously been used to examine the adsorption of analytes
to immobilized antibodies and Similar ligands in affinity
columns. This algorithm was modified to include the revers
ible binding of an analyte to an agent in the mobile phase.
In this method, the column was divided into a large number
of Slices of equal width. As an analyte moved through this
column, its binding to the immobilized ligand and Soluble
agent in each slice was described by using mass balance and
the differential equations for the rates of these reactions.
This System of equations was Solved for that particular Slice
and interval of time by using a fourth-order Runga-Kutta
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protein-bound form. Some plots that were used to study the
extent of this dissociation process are shown in FIG. 4 These
particular results were calculated for S-warfarin at 25 C.
under conditions similar to those used in this study.
This type of plot was also generated for R-warfarin, which
has a slightly faster rate of dissociation from HSA under the
given experimental conditions.

The model used in FIG. 4 assumes 1) that there is an
Sample, 2) that any warfarin which is later released from its

instantaneous removal of all free warfarin from the initial

60

complex with HSA will bind immediately to the extraction

column, and 3) that the concentration of extracted warfarin
65

is much Smaller than the binding capacity of the column.
Based on this model, it was found that roughly 75% of the
S-warfarin that was originally bound to HSA would be
released from this protein and adsorbed to the extraction
column within 10s. This indicated that ordinary immunoaf
finity extractions, which often take Several minutes to
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perform, (Hage, D. S. J. Chromatogr: B 1998, 715, 3.) would

20
could bind to the microcolumn as the concentration of

be much too long for Separating the free and bound fractions
of S-warfarin. An expanded view of this dissociation

injected warfarin was varied.
One question that remained was whether this type of

process, illustrated in FIG. 4 (b), indicated that extraction

microcolumn could be used to extract warfarin on the

times of only a few hundred milliseconds would be required
to isolate the free fraction of S-warfarin while avoiding any
appreciable contamination by warfarin that had been later

millisecond time Scale. This was tested by injecting Samples
that contained only R- or S-warfarin at various flow rates.
The results obtained on the immunoaffinity column were
then compared to those observed for the same Samples and

released from HSA. The same conclusion was reached in

calculations that were performed for R-warfarin.
Although it was useful in FIG. 4 to assume that there was
an exceSS of binding sites in the column and that there was
immediate removal of any non-complexed warfarin from
Solution, this does represent a worst-case Scenario and
probably resulted in estimates for the usable extraction times
which were smaller than those that might be possible in
practice. For instance, either the presence of a finite number
of binding Sites in the column or a finite rate of adsorption
for the non-complexed warfarin would reduce any pertur
bation of the HSA-bound fraction of warfarin as this passes
through the immunoaffinity column. The same thing would
happen if the warfarin in Solution were allowed to reasSo
ciate with HSA instead of being removed by the column. The
effects of eliminating these assumptions will be considered
through the use of computer Simulations. However, the
model used in FIG. 4 was still found to be a good starting
point for estimating the conditions needed in an immunoaf
finity column for isolating a drugs free fraction.
Design of Immunoaffinity Column. Based on FIG. 4, an
extraction time of less than 200 ms was set as the initial goal

flow rates on an inert control column. FIG. 5 shows an

example of such a study. It was found that in 120 ms there

was 95% extraction of a 5x107M warfarin sample (i.e., a

concentration corresponding to the free warfarin content
expected for the warfarin/HSA mixtures examined later in
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to extract warfarin on the same time Scale that was needed

for Separating warfarin's free and protein-bound fractions.
EXAMPLE 2

25

Separation of Free and Bound Warfarin Fractions.
The next Section of this Study began to examine the use of
an immunoaffinity microcolumn to measure the free drug
fractions of mixtures that contained known concentrations of

tures at room temperature. Under these conditions, an error
of less than 20-40% in the measured free fractions of R- and

35

HSA and R- or S-warfarin. This was to be done by moni
toring the fluorescence of any warfarin that passed non
retained through the immunoaffinity column. One difficulty
with this approach is that warfarin has a significant change
in its degree of fluorescence when it is in Solution verSuS
bound to HSA. This, plus the inherent fluorescence of HSA,
created a problem in detection because the non-retained
samples were expected to contain a mixture of HSA, HSA
bound warfarin, and warfarin that had dissociated from
HSA

The approach used to overcome this problem was to pass
the non-retained Sample peaks through a Series of ISRP
40

antibodies. The remainder of the column was filled with

diol-bonded Silica. The purpose of the immunoaffinity Sup
port was to extract warfarin from Samples, while the diol
bonded Silica was used to hold the immunoaffinity Support
in place and to provide uniform Sample application to this
layer.
In this type of column the actual time over which free
drug extraction and Sample perturbation takes place is
represented by the time during which any given part of the
Sample passes through the immunaffinity layer. For instance,

8x10 M warfarin sample shown in FIG. 5, essentially

complete extraction was possible in 60 ms. Thus, it was
concluded that immunoaffinity microcolumns could be used

for the removal of free warfarin from warfarin/HSA mix

S-warfarin was expected due to the dissociation of their
protein-bound fractions. In order to work within this time
frame it was necessary to prepare a column that was 35
capable of operating in the millisecond time domain. This
was accomplished by using a Sandwich microcolumn that
was prepared as described herein. This consisted of a 2.1
mm ID x 1.0 cm tube that was packed with a 1.1 mm thick
layer of a Support that contained immobilized anti-warfarin

this report). At even lower concentrations, Such as the

(internal Surface reversed-phase) columns. This was done by

using the system illustrated in FIG. 6. Although all of the
bound warfarin would eventually be released from HSA in

Such a System, a dissociating agent (1-propanol) was added

to the microcolumn effluent to increase the rate of this
proceSS.
45

50

The 1-propanol also acted as an organic modifier to aid in
the elution of components on the ISRP columns.
A typical chromatogram for this System is shown in FIG.
7. As demonstrated in earlier studies, proteins like HSA are
too large to fit in the pores of an ISRP column and will elute

an effective extraction time of 200 ms or less would be

in its excluded volume. However, Smaller molecules like

obtained by using a flow rate of at least 0.9 mL/min on a 2.1
mm ID column that contains a 1.1 mm layer of an immu
noaffinity support. This is well within the range of usable
conditions for these columns, which have been operated at
flow rates as high as 9-10 mL/min.
The binding capacity of the immunoaffinity columns also
had to be considered to ensure that overloading did not occur
when warfarin Samples were injected onto these columns.
The concentration of warfarin binding sites in one anti
warfarin microcolumn was estimated to be 50 pmol.
Although this is a relatively Small concentration of ligand, it
is still three-to-five times larger than the concentration of
free warfarin that was applied in any Sample, thus indicating
that these columns did have a Sufficient binding capacity for
this present Study. This was confirmed experimentally by
measuring the maximum concentration of warfarin that

warfarin can enter these pores and interact with the hydro
phobic phase that is located there. This will cause these
molecules to be retained and to elute after proteins from
these columns. In the case of this study, the Second peak was
much broader than the first since it was produced by
warfarin that entered the pores at different points along the
column as it began to undergo dissociation from HSA.
ISRP columns have been used alone for the analysis of
free and bound warfarin in the presence of bovine Serum

55
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albumin. In these earlier Studies, the free warfarin was

retained at the beginning of the ISRP column, while the
bound fraction underwent dissociation from albumin and
was retained further downstream. It was shown that this
65

resulted in three overlapping peakS: the first representing the
non-retained protein, the Second corresponding to warfarin

which dissociated from this protein, and the third (and
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slowest eluting peak) representing warfarin's initial free
fraction. It is important to note in this present Study that the
free warfarin peak was not observed on the ISRP column
when the Samples had previously passed through the immu
noaffinity column. This occurred because the free fraction
had now been removed from these samples. This allowed a
much cleaner Separation to be obtained between the bound
and free fractions of this drug and its binding proteins than
was reported when using only ISRP supports.
Various factors were adjusted to obtain the Separation

22
bonded silica or 2) the immunoaffinity column that had
previously been developed for the millisecond-Scale extrac
tion of warfarin. The peak area obtained with the diol
column allowed the total concentration of warfarin in the
Sample to be determined. The area measured after extraction
by the immunoaffinity column allowed the concentration of
bound warfarin to be estimated. By combining these two
values it was then possible to calculate the concentration of
free warfarin in the Sample.
This approach was tested by injecting a Set of Samples that

shown in FIG. 7. The rate of warfarin dissociation from HSA

M HSA. Both the R- and S-warfarin samples were injected
twenty times onto the diol column and immunoaffinity
column. This gave relative standard deviations of +4-6% for
their measured peak areas on the ISRP system. The free
fractions that were obtained for these Samples are shown in

was increased in the ISRP column by adding 1-propanol to
the effluent of the immunoaffinity column. This resulted in
a sharper peak for the bound warfarin fraction Since it was
now released over a shorter distance within the ISRP col

contained 0.95-1.10x10 MR- or S-warfarin and 4.5x10

15

U.

Table 2, below. For R-warfarin, the free fraction was deter

A 7.5% solution of 1-propanol was found to be optimum
for this purpose Since it allowed complete dissociation of
warfarin from HSA in a reasonable time while still providing
a large enough difference in retention for their separation. A
longer length for the ISRP support was also employed

mined to be 11.8+0.6% at 25 C. (or a bound fraction of
88.2%), while for S-warfarin the free fraction was 5.9+0.2%
(or 94.1% bound).
TABLE 2

(going from one 5 cm long column to two 5 cm columns) to

increase the efficiency of this System and its ability to
resolve the HSA and bound warfarin peaks. The result was
a separation in which baseline resolution was obtained
within 5 min of Sample injection.
One Small problem in using multiple ISRP columns was
that this increased the back pressure of the overall chro
matographic System. This placed a limit on the maximum
flow rate and minimum Sample residence time that could be
used with the immunoaffinity microcolumn. As a compro
mise between extraction time, Sample throughput and these
preSSure limitations, an injection flow rate of 1.0 mL/min
was chosen for the final System. This gave a residence time
of 180 ms for samples in the immunoaffinity column. As
noted earlier, this concentration of time not only was Suff
cient to allow the quantitative extraction of warfarin, but it
also fell within the range of 200 ms or less that was initially
Selected for use in Separating warfarin's free and bound
fractions.

Measured and predicted free fractions for R- and S-warfarin
in Samples containing known mixtures of warfarin and HSA"
25

35

40

45

50

55

as a function of the total warfarin concentration in the
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This detection limit was 50 to 100-fold Smaller than the free

presence of 1) a microcolumn that contained only diol

(+0.1) x 10 M and 3.4 (+0.1) x 10 M', respectively.

The accuracy of these free fractions was evaluated by
comparing them with the predicted results for these samples.
This was accomplished by using the known composition of
these Samples and equilibrium constants that have previ
ously been determined for the binding of R- and S-warfarin
to HSA under conditions similar to those used in this study

assumed in these calculations that essentially all of the HSA
was active; this was confirmed experimentally through the
use of fluorescence and a Solution-phase titration of the HSA
with increasing concentrations of warfarin. For R-warfarin,
it was predicted that approximately 10+2% of this drug
would be in the free form at equilibrium for the given sample
composition, while for S-warfarin a predicted free fraction
of 7+1 was obtained. Both predicted results were within one
Standard deviation of the experimental free fractions, thus
indicating that there was good agreement between these
An inherent assumption made throughout this project was
that the anti-warfarin antibodies in the immunoaffinity col
umn would be able to distinguish between the free warfarin
in Solution and its HSA-bound fraction. For this to be true,

for these enantiomers was about 0.5-1x10 M (S/N=2).

warfarin concentrations which were measured in this study.
The warfarin and HSA mixtures that were being used as
test Samples were now injected onto the same System in the

10 (+2) 7%
7 (+1) 7%

values.

the extraction column. The area of the warfarin that eluted

0-1.7x10 M. The lower limit of detection of this method

11.8 (+0.6) 7%
5.9 (+0.2) 7%

(Loun, B.; Hage, D. S. Anal. Chem. 1994, 66,3814). It was

injected onto the system shown in FIG. 6, with diol-bonded
Silica being used in place of the immunoaffinity Support in

Sample. Both R- and S-warfarin gave linear responses in
these plots with correlation coefficients of 0.9991-0.9993
for ten Samples that contained warfarin concentrations of

R-Warfarin
S-Warfarin

The predicted free fractions were determined by using the known compo

S-warfarin were mixed with HSA. These mixtures were then

from the ISRP columns (now corresponding to both the
bound and free warfarin fractions) was measured and plotted

Fraction

sitions of the samples and equilibrium constants which have previously
been measured for the binding of warfarin enantiomers to HSA at 25 C.
The equilibrium constants that were used for R- and S-warfarin were 2.6

warfarin in known mixtures of warfarin and HSA. To

quantitate the free warfarin in these samples, Standard curves
were first prepared in which various concentrations of R- or

Predicted free

Fraction

All values shown in parentheses represent a range of t1 SD.

EXAMPLE 3

Analysis of Free Warfarin Fractions
The fourth phase of this study used the immunoaffinity
and ISRP system to measure the concentration of free

Measured Free

Compound

65

these antibodies would have to interact with regions in the
Structure of warfarin that were not exposed when this drug
was complexed with HSA. The agreement between the
actual and predicted results in Table 2 indicates that this was
indeed the case. This specificity for the free versus bound
fractions was not Surprising in the case of R-warfarin, which
is believed to interact deep within its binding site on HSA.
But a similar specificity was noted for S-warfarin, which is
thought to interact more with HSA's outer Surface. This
result indicates that it should be possible to use immunoaf
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(free plus dissociated warfarin) to approach the concentra
tion of free warfarin that was actually removed from the
Sample.
One observation that can be made by comparing the two
plots in FIG. 8 is that there will be an optimum flow rate
range over which the best estimates can be made of a drug's
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finity chromatography to isolate the free fractions of drugs
that have a variety of different orientations in their drug
protein complexes. However, as a precaution, it is still
recommended that antibody Specificity always be consid
ered for any new compounds that are to be examined by this
analytical technique.

true free fraction. For instance, FIG. 8 shows that the extent

of warfarin dissociation from HSA will be minimized by
operating at high flow rates; however, this decreases extrac
tion of the free warfarin fraction. Working at slower flow
rates provides a better extraction efficiency but suffers from
greater errors due to bound drug dissociation. It is only at

EXAMPLE 4

Simulation of Warfarin Extraction and Dissociation
After the free fractions of R- and S-warfarin had been

determined in test Samples, a comparison was made between
the accuracy of these values and the errors that had been
anticipated due to the dissociation of bound warfarin during
Such measurements. For instance, the differences in the

intermediate flow rates that a balance is obtained between
15

measured and predicted free fractions in Table 2 (+18% for
R-warfarin and -16% for S-warfarin) were much smaller
than the errors of 20-40% that were expected from FIG. 4
and related plots at comparable extraction times. It was
Suspected from this that these earlier graphs had overesti
mated the role played by dissociation effects during the
isolation of free drug fractions by immunoaffinity chroma
tography.
A more complete picture of the immunoaffinity extraction
proceSS was obtained through the use of computer Simula
tions. This was accomplished by developing a model which
no longer made the same assumptions that were used in FIG.

for R- and S-warfarin under these flow rate conditions.
Another observation that can be made from FIG. 8 is that

the free fraction errors predicted by the Simulations were
less than those that were originally estimated through the use
of Simple drug-protein dissociation. For instance, it was
determined from FIG. 4 that dissociation of S-warfarin from
25

4. For instance, this model allowed the free and dissociated

extraction on the immunoaffinity microcolumn. It was also
now possible to consider the use of a column with a finite
binding capacity and Samples in which any non-complexed
warfarin could bind to HSA instead of the immobilized
35

analytes to affinity supports, (Hage, D. S.; Walters, R. R. J.

Chromatogr: 1988, 436, 111; Rollag, J. G.; Hage, D. S. J.
Chromatogr: A 1998, 795, 185; and Hage, D. S.; Thomas, D.
H.; Roy Chowdhuri, A.; Clarke, W. Anal. Chem. 1999, 71,

2965.) with the inclusion of a reversible solution-phase

R-warfarin. Similar plots were generated for S-warfarin. The
Sample and column conditions that were used in these
Simulations were the same as those that were present in the
experimental determination of the free warfarin fractions.
The rate constant for adsorption of warfarin to the immo
bilized antibodies was estimated from the earlier studies that

examined the extraction of R- and S-warfarin by the immu
noaffinity column.
The lower plot in FIG. 8 shows how the extraction
efficiency of warfarin was predicted to change as this drug
was injected at various flow rates. This extraction had its
highest efficiency at low flow rates and a decreasing effi
ciency at higher flow rates. This occurs because there is a
Smaller contact time between the Sample and the immobi
lized antibodies as higher application flow rates are used.
The top plot in FIG. 8 shows how the relative concentra
tion of extracted warfarin compared to the true free fraction
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column residence times resulted in less dissociation effects.

This, in turn, allowed the concentration of extracted warfarin

equivalents. While Some of the examples and descriptions
above include Some conclusions about the way the invention
may function, the inventor does not intend to be bound by
those conclusions and functions, but puts them forth only as
possible explanations.
It is to be further understood that the specific embodi
ments of the present invention as Set forth are not intended
as being exhaustive or limiting of the invention, and that
many alternatives, modifications, and variations will be
apparent to those of ordinary skill in the art in light of the
foregoing examples and detailed description. Accordingly,
this invention is intended to embrace all Such alternatives,

modifications, and variations that fall within the Spirit and
Scope of the following claims.
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What is claimed is:
1. A method to determine the concentration of a free

analyte fraction in a Sample, the Sample comprising a
biological fluid having a bound analyte fraction and the free
analyte fraction, the method comprising:

(a) applying, the sample to an affinity column having an
60

in warfarin/HSA mixtures when the bound warfarin in these

Samples was allowed to undergo dissociation and rebinding
to the HSA. As expected, higher flow rates and shorter

HSA would increase the measured free fraction of this drug
by 25-30% at an extraction time of 180 ms. However, the
more complete model used in the Simulations indicated that
a maximum error of only 15% would be expected.
In light of the detailed description of the invention and the
examples presented above, it can be appreciated that the
Several aspects of the invention are achieved.
It is to be understood that the present invention has been
described in detail by way of illustration and example in
order to acquaint otherS Skilled in the art with the invention,
its principles, and its practical application. Particular for
mulations and processes of the present invention are not
limited to the descriptions of the Specific embodiments
presented, but rather the descriptions and examples should
be viewed in terms of the claims that follow and their

reaction between the injected drug and its binding proteins.
Further details on this approach can be found in the Methods
and Materials.
FIG. 8 shows the simulation results that were obtained for

mL/min was needed to obtain an error of +15% or less in the

measured free fractions. This compares well with the
approximate errors of +18% and -16% that were estimated

warfarin to undergo a continuous (rather than instantaneous)

antibodies. This was accomplished by adapting a previous
algorithm that has been used to study the adsorption of

accuracy and extraction recovery. In this particular case, it
was predicted that a flow rate range of roughly 0.9-1.6

active layer which Selectively binds free analyte rela
tive to bound analyte wherein the active layer Separates
the free analyte fraction from the bound analyte frac
tion of the Sample in the millisecond time domain;

(b) detection of signal from the free analyte fraction
65

Separated from the Sample, and

(c) determining the concentration of free analyte present
in the Sample.
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2. The method of claim 1 wherein the affinity column
comprises an active layer, the active layer comprising Sup
port particles derivatized with a binding agent.
3. The method of claim 2 wherein the active layer is from
about 10 microns to about 1.1 millimeters in length.
4. The method of claim 2 wherein the active layer is not
less than 60 microns in length.
5. The method of claim 2 wherein the binding agent is
Selected from the group of agents consisting of antibodies,
aptamers, antibody fragments, Synthetic molecular imprints,
antibody related molecules and recombinant proteins.
6. The method of claim 5 wherein the binding agent is
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(a) applying the sample to an affinity column wherein the
column Separates the free analyte fraction from the
Sample in the millisecond time domain;

(b) detection of signal from the free analyte fraction
Separated from the Sample, and

(c) comparing the Signal detected in (b) to a standard
1O

antibodies.

7. The method of claim 6 wherein the binding agent has
a high binding affinity for the free analyte fraction.
8. The method of claim 7 wherein the binding agent has

15

a binding affinity for the free analyte fraction from about 10

to about 10 M.

9. The method of claim 7 wherein the binding agent has
a binding affinity for the free analyte fraction greater than

about 10 M'.

10. The method of claim 7 wherein the free analyte
fraction is separated from the Sample from about 1 to about
500 milliseconds after injection of the sample into the
microcolumn.

11. The method of claim 10 wherein the free analyte
fraction is separated from the Sample from about 1 to about
100 milliseconds after injection of the sample into the

25

microcolumn.

12. The method of claim 10 wherein the signal is detected
from the free analyte fraction by an off-line method or an

on-line method.

13. The method of claim 12 wherein the signal is detected
by an on-line method with direct detection.
14. The method of claim 12 wherein the signal is detected
by a method Selected from the group consisting of
immunoassay, mass spectrometry, gas chromatography,

between about 1:1 to about 10:1.
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23. The method of claim 22 wherein the sample is injected
onto the column at a flow rate of about 0.01 to about 9.0

ultraViolet absorbance, fluorescence detectors, and electro

milliliters per minute.
24. The method of claim 23 wherein the sample is injected
onto the column at a pressure of about 100 to about 1500 psi.

chemical detectors.
15. A method to determine the concentration of a free

analyte fraction in a Sample, the Sample comprising a bound
analyte fraction and the free analyte fraction, the method
comprising:

thereby determining the concentration of free analyte
present in the Sample.
16. The method of claim 12 wherein the active layer is
introduced by a plurality of injections.
17. The method of claim 16 wherein the active layer is
introduced by about 10 to about 100 injections.
18. The method of claim 17 wherein the active layer is
introduced by about 30 to about 40 injections when the
active layer is from about 100 to about 500 microns in
length.
19. The method of claim 17 wherein the active layer is
introduced by about 60 to about 80 injections when the
active layer is from about 60 to about 100 microns in length.
20. The method of claim 17 wherein the support particles
comprising the active layer are injected onto the column at
a density of from about 0.1 to about 20 milligrams of support
particle per milliliter of packing Solvent.
21. The method of claim 16 wherein the biological fluid
is Selected from the group consisting of blood, plasma, urine,
cerebroSpinal fluid, a tissue Sample, and intracellular fluid.
22. The method of claim 21 wherein the binding capacity
of the active layer comprises a ratio of the number of active
binding sites to amount of free analyte present in the Sample

40
k

k

k

k

k

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.

: 6,720,193 B2

Page 1 of 1

APPLICATIONNO. : 09/794857

DATED
INVENTOR(S)

: April 13, 2004
: David S. Hage and William A. Clarke

It is certified that error appears in the above-identified patent and that said Letters Patent is
hereby corrected as shown below:

Column 1
Line 10, delete “5 R01.

Signed and Sealed this
Twentieth Day of May, 2008

WDJ
JON. W. DUDAS

Director of the United States Patent and Trademark Office

